Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Collegium Pharmaceutical
COLL
5
Enerpac Tool
EPAC
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash cash equivalents and federal funds sold | 77.58%554M | 77.58%554M | 18.29%510.14M | -4.08%435.7M | -14.81%452.7M | -18.36%311.97M | -18.36%311.97M | -6.51%431.27M | 34.86%454.21M | 42.18%531.44M |
-Cash and cash equivalents | 94.10%377.83M | 94.10%377.83M | 83.21%357.85M | -22.36%259.27M | -17.29%327.36M | -25.44%194.66M | -25.44%194.66M | -42.50%195.32M | 22.69%333.93M | 49.81%395.8M |
-Restricted cash and investments | 50.17%176.16M | 50.17%176.16M | -35.46%152.28M | 46.68%176.44M | -7.59%125.34M | -3.11%117.31M | -3.11%117.31M | 94.09%235.95M | 86.10%120.28M | 23.80%135.64M |
Receivables | -16.48%167.77M | -16.48%167.77M | 13.79%197.15M | 3.95%197.11M | 6.98%194.5M | 19.19%200.87M | 19.19%200.87M | 12.40%173.26M | 44.02%189.62M | 46.85%181.81M |
-Accounts receivable | -16.48%167.77M | -16.48%167.77M | 13.79%197.15M | 3.95%197.11M | 6.98%194.5M | 19.19%200.87M | 19.19%200.87M | 12.40%173.26M | 44.02%189.62M | 46.85%181.81M |
Net loan | -11.21%17.95B | -11.21%17.95B | -4.71%18.9B | -6.70%19.11B | -9.25%19.3B | -4.56%20.22B | -4.56%20.22B | -2.33%19.84B | 1.76%20.49B | 12.28%21.26B |
-Gross loan | -10.36%18.4B | -10.36%18.4B | -3.98%19.31B | -6.06%19.47B | -8.27%19.63B | -3.55%20.53B | -3.55%20.53B | -1.44%20.11B | 2.55%20.72B | 12.58%21.4B |
-Allowance for loans and lease losses | 45.06%448.3M | 45.06%448.3M | 49.24%404.92M | 49.52%354.07M | 146.71%331.65M | 210.86%309.04M | 210.86%309.04M | 192.97%271.32M | 205.75%236.8M | 96.94%134.43M |
Securities and investments | -27.50%533.26M | -27.50%533.26M | -0.80%715.8M | -12.88%665.71M | -7.35%716.07M | -9.84%735.56M | -9.84%735.56M | -18.93%721.59M | -16.34%764.12M | -11.08%772.89M |
-Available for sale securities | 20.61%32.49M | 20.61%32.49M | 17.47%32.38M | 23.04%35.24M | -8.01%26.75M | -6.94%26.94M | -6.94%26.94M | -96.90%27.57M | -96.86%28.64M | -96.65%29.08M |
-Held to maturity securities | -32.87%406.96M | -32.87%406.96M | -1.02%585.93M | -15.32%532.04M | -6.91%589M | -9.98%606.25M | -9.98%606.25M | --591.95M | --628.26M | --632.74M |
-Short term investments | -8.36%93.81M | -8.36%93.81M | -4.50%97.49M | -8.19%98.44M | -9.68%100.32M | -9.72%102.37M | -9.72%102.37M | --102.08M | --107.22M | --111.07M |
Long term equity investment | 3.31%2.17B | 3.31%2.17B | 0.23%2.08B | 1.53%2.1B | 13.51%2.11B | 13.51%2.1B | 13.51%2.1B | 18.18%2.07B | 25.92%2.07B | 37.08%1.86B |
Derivative assets | 176.68%175.52M | 176.68%175.52M | -43.89%74.64M | -10.73%70.53M | -14.18%82.92M | -41.60%63.44M | -41.60%63.44M | -47.04%133.02M | -38.62%79.01M | 58.73%96.62M |
Assets held for sale | --0 | --0 | --0 | --0 | --0 | --290.94M | --290.94M | ---- | ---- | ---- |
Goodwill and other intangible assets | -1.31%320.55M | -1.31%320.55M | -1.79%320.01M | -1.82%322.11M | -1.08%323.11M | -1.16%324.81M | -1.16%324.81M | -2.13%325.84M | -2.01%328.08M | 1.44%326.64M |
-Goodwill | 0.00%259.85M | 0.00%259.85M | 0.00%259.85M | 0.00%259.85M | 0.00%259.85M | 0.00%259.85M | 0.00%259.85M | 0.00%259.85M | 0.00%259.85M | 0.00%259.85M |
-Other intangible assets | -6.56%60.7M | -6.56%60.7M | -8.83%60.16M | -8.75%62.26M | -5.28%63.27M | -5.53%64.97M | -5.53%64.97M | -9.72%65.99M | -8.98%68.23M | 7.48%66.8M |
Other assets | -10.11%40.68B | -10.11%40.68B | -11.08%41.44B | -15.61%41.18B | -17.83%43B | -16.51%45.25B | -16.51%45.25B | -16.56%46.6B | -17.96%48.8B | -11.53%52.33B |
Total assets | -10.00%62.56B | -10.00%62.56B | -8.62%64.23B | -12.41%64.09B | -14.46%66.17B | -12.07%69.5B | -12.07%69.5B | -12.14%70.29B | -11.95%73.17B | -4.72%77.35B |
Liabilities | ||||||||||
Federal funds purchased and securities sold under agreement to repurchase | -21.74%8.34B | -21.74%8.34B | -10.39%9.17B | -14.46%9.33B | -13.03%9.52B | -1.36%10.65B | -1.36%10.65B | -2.94%10.23B | 5.72%10.91B | 22.69%10.94B |
Payables | 2.35%202.34M | 2.35%202.34M | 6.89%189.21M | 0.85%181.27M | 2.89%197.4M | 2.60%197.7M | 2.60%197.7M | 0.38%177.02M | -0.55%179.74M | -6.58%191.85M |
-Dividends payable | 6.86%163.38M | 6.86%163.38M | 7.16%163.67M | 0.66%153.42M | 0.60%153.17M | 0.91%152.89M | 0.91%152.89M | 1.69%152.74M | 1.62%152.42M | 2.37%152.27M |
-Due to related parties | -13.07%38.96M | -13.07%38.96M | 5.19%25.54M | 1.92%27.85M | 11.73%44.23M | 8.81%44.82M | 8.81%44.82M | -7.13%24.28M | -11.15%27.33M | -30.08%39.58M |
Current debt and capital lease obligation | -20.57%831.32M | -20.57%831.32M | -18.40%790.49M | -29.16%861.88M | -33.53%1.01B | -20.80%1.05B | -20.80%1.05B | -22.15%968.73M | 8.51%1.22B | 54.07%1.52B |
-Current debt | -20.57%831.32M | -20.57%831.32M | -18.40%790.49M | -29.16%861.88M | -33.53%1.01B | -20.80%1.05B | -20.80%1.05B | -22.15%968.73M | 8.51%1.22B | 54.07%1.52B |
Long term debt and capital lease obligation | 4.55%8.17B | 4.55%8.17B | -4.53%7.95B | 0.79%8.19B | -4.59%8.01B | -6.76%7.82B | -6.76%7.82B | 7.83%8.33B | 4.18%8.13B | 8.30%8.39B |
-Long term debt | 4.55%8.17B | 4.55%8.17B | -4.53%7.95B | 0.79%8.19B | -4.59%8.01B | -6.76%7.82B | -6.76%7.82B | 7.83%8.33B | 4.18%8.13B | 8.30%8.39B |
Derivative product liabilities | -7.39%94.89M | -7.39%94.89M | 37.95%118.16M | -21.90%76.13M | -4.80%74.65M | 12.10%102.47M | 12.10%102.47M | 3.49%85.66M | 76.80%97.48M | 102.55%78.41M |
Liabilities of discontinued operations | --0 | --0 | --0 | --0 | --0 | --193.69M | --193.69M | ---- | ---- | ---- |
Other liabilities | -11.18%37.72B | -11.18%37.72B | -10.77%38.73B | -15.34%38.48B | -17.90%40.33B | -16.81%42.47B | -16.81%42.47B | -18.20%43.4B | -19.60%45.45B | -12.89%49.12B |
Total liabilities | -11.39%55.36B | -11.39%55.36B | -9.89%56.95B | -13.43%57.12B | -15.81%59.13B | -13.03%62.48B | -13.03%62.48B | -13.23%63.2B | -13.19%65.98B | -5.44%70.24B |
Shareholders'equity | ||||||||||
Share capital | 7.51%3.45M | 7.51%3.45M | 7.55%3.45M | 1.22%3.24M | 1.16%3.23M | 0.85%3.21M | 0.85%3.21M | 1.10%3.21M | 1.11%3.2M | 1.69%3.2M |
-common stock | 7.51%3.45M | 7.51%3.45M | 7.55%3.45M | 1.22%3.24M | 1.16%3.23M | 0.85%3.21M | 0.85%3.21M | 1.10%3.21M | 1.11%3.2M | 1.69%3.2M |
-Preferred stock | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Paid-in capital | 7.81%6.32B | 7.81%6.32B | 7.79%6.31B | 1.09%5.91B | 1.02%5.89B | 0.99%5.86B | 0.99%5.86B | 1.32%5.86B | 1.32%5.84B | 2.06%5.83B |
Retained earnings | -53.48%235.32M | -53.48%235.32M | -40.90%346.18M | -37.21%432.68M | -24.31%507.62M | -34.24%505.88M | -34.24%505.88M | -24.82%585.76M | -6.03%689.15M | 0.12%670.69M |
Less: Treasury stock | 0.00%138.02M | 0.00%138.02M | 0.00%138.02M | 0.00%138.02M | 0.00%138.02M | 0.00%138.02M | 0.00%138.02M | 0.00%138.02M | 0.00%138.02M | 0.00%138.02M |
Gains losses not affecting retained earnings | -11.45%13.59M | -11.45%13.59M | 15.18%16.26M | -19.79%13.92M | -29.17%14.06M | -26.74%15.35M | -26.74%15.35M | -38.03%14.11M | -40.09%17.36M | -44.35%19.85M |
Total stockholders'equity | 2.98%6.44B | 2.98%6.44B | 3.46%6.54B | -3.06%6.22B | -1.72%6.27B | -3.27%6.25B | -3.27%6.25B | -1.95%6.32B | 0.32%6.41B | 1.63%6.38B |
Non controlling interests | -2.01%756.37M | -2.01%756.37M | -3.83%742.89M | -2.98%755.3M | 4.46%767.43M | 4.84%771.89M | 4.84%771.89M | 7.47%772.44M | 10.71%778.48M | 16.62%734.67M |
Total equity | 2.43%7.19B | 2.43%7.19B | 2.67%7.28B | -3.05%6.97B | -1.08%7.04B | -2.44%7.02B | -2.44%7.02B | -1.01%7.09B | 1.35%7.19B | 3.00%7.12B |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |